Tumor necrosis factor receptor 2 (TNFR2), also known as tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) and CD120b, is one of two membrane receptors that binds tumor necrosis factor-alpha (TNFα).[5][6] Like its counterpart, tumor necrosis factor receptor 1 (TNFR1), the extracellular region of TNFR2 consists of four cysteine-rich domains which allow for binding to TNFα.[7][8] TNFR1 and TNFR2 possess different functions when bound to TNFα due to differences in their intracellular structures, such as TNFR2 lacking a death domain (DD).[7]
Function
editThe protein encoded by this gene is a member of the tumor necrosis factor receptor superfamily, which also contains TNFRSF1A. This protein and TNF-receptor 1 form a heterocomplex that mediates the recruitment of two anti-apoptotic proteins, c-IAP1 and c-IAP2, which possess E3 ubiquitin ligase activity. The function of IAPs in TNF-receptor signalling is unknown, however, c-IAP1 is thought to potentiate TNF-induced apoptosis by the ubiquitination and degradation of TNF-receptor-associated factor 2 (TRAF2), which mediates anti-apoptotic signals. Knockout studies in mice also suggest a role of this protein in protecting neurons from apoptosis by stimulating antioxidative pathways.[9]
Clinical significance
editCNS
editAt least partly because TNFR2 has no intracellular death domain, TNFR2 is neuroprotective.[10]
Patients with schizophrenia have increased levels of soluble tumor necrosis factor receptor 2 (sTNFR2).[11]
Cancer
editTargeting of TNRF2 in tumor cells is associated with increased tumor cell death and decreased progression of tumor cell growth.[8]
Increased expression of TNFR2 is found in breast cancer, cervical cancer, colon cancer, and renal cancer.[8] A link between the expression of TNRF2 in tumor cells and late-stage cancer has been discovered.[8] TNFR2 plays a significant role in tumor cell growth as it has been found that the loss of TNFR2 expression is linked with increased death of associated tumor cells and a significant standstill of further growth.[8] There is therapeutic potential in the targeting of TNFR2 for cancer treatments through TNFR2 inhibition.[12]
Systemic Lupus Erythematous (SLE)
editA small scale study of 289 Japanese patients suggested a minor increased predisposition from an amino acid substitution of the 196 allele at exon 6. Genomic testing of 81 SLE patients and 207 healthy patients in a Japanese study showed 37% of SLE patients had a polymorphism on position 196 of exon 6 compared to 18.8% of healthy patients. The TNFR2 196R allele polymorphism suggests that even one 196R allele results in increased risk for SLE.[13]
Interactions
editTNFRSF1B has been shown to interact with:
References
edit- ^ a b c GRCh38: Ensembl release 89: ENSG00000028137 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028599 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, et al. (April 1990). "Molecular cloning and expression of a receptor for human tumor necrosis factor". Cell. 61 (2): 361–370. doi:10.1016/0092-8674(90)90816-W. PMID 2158863. S2CID 36187863.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ Santee SM, Owen-Schaub LB (August 1996). "Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization". The Journal of Biological Chemistry. 271 (35): 21151–21159. doi:10.1074/jbc.271.35.21151. PMID 8702885.
- ^ a b Wang J, Al-Lamki RS (2013-11-17). "Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinoma". BioMed Research International. 2013: 821310. doi:10.1155/2013/821310. PMC 3848079. PMID 24350291.
- ^ a b c d e Sheng Y, Li F, Qin Z (2018). "TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors". Frontiers in Immunology. 9: 1170. doi:10.3389/fimmu.2018.01170. PMC 5985372. PMID 29892300.
- ^ "Entrez Gene: TNFRSF1B tumor necrosis factor receptor superfamily, member 1B". Retrieved 8 May 2017.
- ^ Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, Maudsley S (October 2008). "Targeting TNF-alpha receptors for neurotherapeutics". Trends in Neurosciences. 31 (10): 504–511. doi:10.1016/j.tins.2008.07.005. PMC 2574933. PMID 18774186.
- ^ Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, et al. (July 2018). "Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associated with Hippocampal Volume and Cognitive Performance in Patients with Schizophrenia". The International Journal of Neuropsychopharmacology. 21 (7): 631–639. doi:10.1093/ijnp/pyy013. PMC 6031046. PMID 29529289.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ Medler J, Wajant H (April 2019). "Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target". Expert Opinion on Therapeutic Targets. 23 (4): 295–307. doi:10.1080/14728222.2019.1586886. PMID 30856027. S2CID 75139844.
- ^ Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K (June 1999). "Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus". Tissue Antigens. 53 (6): 527–533. doi:10.1034/j.1399-0039.1999.530602.x. PMID 10395102.
- ^ Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, et al. (February 2004). "A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway". Nature Cell Biology. 6 (2): 97–105. doi:10.1038/ncb1086. PMID 14743216. S2CID 11683986.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ Song HY, Donner DB (August 1995). "Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumour necrosis factor receptor". The Biochemical Journal. 309 (3): 825–829. doi:10.1042/bj3090825. PMC 1135706. PMID 7639698.
- ^ Takeuchi M, Rothe M, Goeddel DV (August 1996). "Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins". The Journal of Biological Chemistry. 271 (33): 19935–19942. doi:10.1074/jbc.271.33.19935. PMID 8702708.
- ^ Hostager BS, Bishop GA (April 2002). "Role of TNF receptor-associated factor 2 in the activation of IgM secretion by CD40 and CD120b". Journal of Immunology. 168 (7): 3318–3322. doi:10.4049/jimmunol.168.7.3318. PMID 11907088.
- ^ Rothe M, Xiong J, Shu HB, Williamson K, Goddard A, Goeddel DV (August 1996). "I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction". Proceedings of the National Academy of Sciences of the United States of America. 93 (16): 8241–8246. Bibcode:1996PNAS...93.8241R. doi:10.1073/pnas.93.16.8241. PMC 38654. PMID 8710854.
- ^ Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A (May 1997). "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1". The Journal of Biological Chemistry. 272 (22): 14029–14032. doi:10.1074/jbc.272.22.14029. PMID 9162022.
- ^ Carpentier I, Coornaert B, Beyaert R (October 2008). "Smurf2 is a TRAF2 binding protein that triggers TNF-R2 ubiquitination and TNF-R2-induced JNK activation". Biochemical and Biophysical Research Communications. 374 (4): 752–757. doi:10.1016/j.bbrc.2008.07.103. PMID 18671942.
- ^ Pype S, Declercq W, Ibrahimi A, Michiels C, Van Rietschoten JG, Dewulf N, et al. (June 2000). "TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation". The Journal of Biological Chemistry. 275 (24): 18586–18593. doi:10.1074/jbc.M000531200. PMID 10764746.
{{cite journal}}: CS1 maint: overridden setting (link)
Further reading
edit- Kollias G, Kontoyiannis D (2003). "Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments". Cytokine & Growth Factor Reviews. 13 (4–5): 315–321. doi:10.1016/S1359-6101(02)00019-9. PMID 12220546.
- Holtmann MH, Schuchmann M, Zeller G, Galle PR, Neurath MF (2003). "The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders". Archivum Immunologiae et Therapiae Experimentalis. 50 (4): 279–288. PMID 12371624.
- Horiuchi T, Kiyohara C, Tsukamoto H, Sawabe T, Furugo I, Yoshizawa S, et al. (March 2007). "A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis". Annals of the Rheumatic Diseases. 66 (3): 320–324. doi:10.1136/ard.2006.058917. PMC 1856025. PMID 17028114.
{{cite journal}}: CS1 maint: overridden setting (link)
External links
edit- CD120b+Antigen at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
This article on a gene on human chromosome 1 is a stub. You can help Wikipedia by expanding it. |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |